Rilpivirine

(Edurant®)

Rilpivirine

Drug updated on 11/10/2023

Dosage FormTablet (oral; 25 mg)
Drug ClassHuman immunodeficiency virus type 1 (HIV-1) specific, nonnucleoside reverse transcriptase inhibitor (NNRTI)
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 12 years of age and older and weighing at least 35 kg with HIV-1 RNA less than or equal to 100,000 copies/mL.
  • Indicated in combination with VOCABRIA (cabotegravir), for short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

Product Monograph / Prescribing Information

Document TitleYearSource
Edurant (rilpivirine) Prescribing Information.2022Janssen Therapeutics, Titusville, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines